UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Clinical development of new drug-radiotherapy combinations

Sharma, RA; Plummer, R; Stock, JK; Greenhalgh, TA; Ataman, O; Kelly, S; Clay, R; ... Wedge, SR; + view all (2016) Clinical development of new drug-radiotherapy combinations. NATURE REVIEWS CLINICAL ONCOLOGY , 13 (10) pp. 627-642. 10.1038/nrclinonc.2016.79. Green open access

[thumbnail of nrclinonc.2016.79.pdf]
Preview
Text
nrclinonc.2016.79.pdf - Published Version

Download (523kB) | Preview

Abstract

In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures include the use of radiotherapy, either as a single modality or combined with other treatments. Radiotherapy can provide enormous benefit to patients with cancer. In the past decade, significant technical advances, such as image-guided radiotherapy, intensity-modulated radiotherapy, stereotactic radiotherapy, and proton therapy enable higher doses of radiotherapy to be delivered to the tumour with significantly lower doses to normal surrounding tissues. However, apart from the combination of traditional cytotoxic chemotherapy with radiotherapy, little progress has been made in identifying and defining optimal targeted therapy and radiotherapy combinations to improve the efficacy of cancer treatment. The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) formed a Joint Working Group with representatives from academia, industry, patient groups and regulatory bodies to address this lack of progress and to publish recommendations for future clinical research. Herein, we highlight the Working Group's consensus recommendations to increase the number of novel drugs being successfully registered in combination with radiotherapy to improve clinical outcomes for patients with cancer.

Type: Article
Title: Clinical development of new drug-radiotherapy combinations
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/nrclinonc.2016.79
Publisher version: http://dx.doi.org/10.1038/nrclinonc.2016.79
Language: English
Additional information: © 2016 Macmillan Publishers Limited, part of Springer Nature
Keywords: Science & Technology, Life Sciences & Biomedicine, Oncology, CELL LUNG-CANCER, SURROGATE END-POINTS, ADVANCED RECTAL-CANCER, POSITRON-EMISSION-TOMOGRAPHY, MOLECULARLY TARGETED AGENTS, III RANDOMIZED-TRIAL, EARLY BREAST-CANCER, PHASE-I TRIALS, RADIATION-THERAPY, PROSTATE-CANCER
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Med Phys and Biomedical Eng
URI: https://discovery.ucl.ac.uk/id/eprint/1504246
Downloads since deposit
139Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item